Published in Drug Law Weekly, May 29th, 2007
These targets are the Aurora and FLT kinases, believed to be key to the regulation of cell division and proliferation, which control different stages in the development of a tumour. It is believed that a drug simultaneously able to inhibit the function of both targets will be more effective against cancer than an inhibitor that acts on a single target. The associated patent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly